WO2009081440A3 - Allergens and allergoids from bee venom - Google Patents

Allergens and allergoids from bee venom Download PDF

Info

Publication number
WO2009081440A3
WO2009081440A3 PCT/IT2008/000767 IT2008000767W WO2009081440A3 WO 2009081440 A3 WO2009081440 A3 WO 2009081440A3 IT 2008000767 W IT2008000767 W IT 2008000767W WO 2009081440 A3 WO2009081440 A3 WO 2009081440A3
Authority
WO
WIPO (PCT)
Prior art keywords
bee venom
preparation
allergoids
immunotherapy
allergens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2008/000767
Other languages
French (fr)
Other versions
WO2009081440A2 (en
Inventor
Giovanni Mistrello
Daniela Roncarolo
Dario Zanoni
Paolo Falagiani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lofarma SpA
Original Assignee
Lofarma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lofarma SpA filed Critical Lofarma SpA
Priority to CA2708879A priority Critical patent/CA2708879C/en
Priority to EP08865110.4A priority patent/EP2222337B1/en
Priority to ES08865110.4T priority patent/ES2561594T3/en
Priority to US12/809,503 priority patent/US8637037B2/en
Priority to RU2010130532/15A priority patent/RU2481122C2/en
Publication of WO2009081440A2 publication Critical patent/WO2009081440A2/en
Publication of WO2009081440A3 publication Critical patent/WO2009081440A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Insects & Arthropods (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.
PCT/IT2008/000767 2007-12-21 2008-12-16 Allergens and allergoids from bee venom Ceased WO2009081440A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2708879A CA2708879C (en) 2007-12-21 2008-12-16 Allergens and allergoids from bee venom
EP08865110.4A EP2222337B1 (en) 2007-12-21 2008-12-16 Allergens and allergoids from bee venom
ES08865110.4T ES2561594T3 (en) 2007-12-21 2008-12-16 Allergens and allergoids from bee venom
US12/809,503 US8637037B2 (en) 2007-12-21 2008-12-16 Allergens and allergoids from bee venom
RU2010130532/15A RU2481122C2 (en) 2007-12-21 2008-12-16 Apitoxin allergens and allergoids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002421A ITMI20072421A1 (en) 2007-12-21 2007-12-21 ALLERGENS AND ALLERGOIDS FROM POISON TO BEES
ITMI2007A002421 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009081440A2 WO2009081440A2 (en) 2009-07-02
WO2009081440A3 true WO2009081440A3 (en) 2009-09-17

Family

ID=40315650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000767 Ceased WO2009081440A2 (en) 2007-12-21 2008-12-16 Allergens and allergoids from bee venom

Country Status (7)

Country Link
US (1) US8637037B2 (en)
EP (1) EP2222337B1 (en)
CA (1) CA2708879C (en)
ES (1) ES2561594T3 (en)
IT (1) ITMI20072421A1 (en)
RU (1) RU2481122C2 (en)
WO (1) WO2009081440A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0904036A2 (en) * 2009-10-07 2011-06-14 Univ Minas Gerais Production process of bioproducts made from isolated apitoxin components of apis mellifera bees, composition and use
US10232048B1 (en) 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
DE102018113509A1 (en) 2018-06-06 2019-12-12 Philipps-Universität Marburg Microemulsion for dermal hyposensitization with allergens
RU2702120C1 (en) * 2018-08-15 2019-10-04 Общество с ограниченной ответственностью Международный центр традиционной и альтернативной медицины "АПИ" под руководством И.В. Кривопалова - Москвина Treatment of multiple sclerosis according to the method of krivopalov-moskvin
RU2731509C1 (en) * 2019-09-09 2020-09-03 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Method for production of bee venom allergoid for carrying out allergen-specific immunotherapy
KR102634320B1 (en) * 2022-12-08 2024-02-08 주식회사 파나큐라 Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
US20060127394A1 (en) * 2004-12-14 2006-06-15 Thomas Grunwald Cloning of honey bee allergen
US20070003579A1 (en) * 2005-06-30 2007-01-04 Mannkind Corporation Allergen-specific immunotherapy
EP1767543A1 (en) * 2000-02-18 2007-03-28 Anergis Sa Novel bee venom polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2279888C1 (en) * 2004-11-17 2006-07-20 Вера Николаевна Федосеева Bee venum allergoid for allergen-specific therapy of patients with allergic response for bee stinging and method for its preparing
KR100744755B1 (en) * 2006-03-31 2007-08-01 권기록 Method of Isolating Melitin Using Bee Venom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767543A1 (en) * 2000-02-18 2007-03-28 Anergis Sa Novel bee venom polypeptides and methods of use thereof
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
US20060127394A1 (en) * 2004-12-14 2006-06-15 Thomas Grunwald Cloning of honey bee allergen
WO2006063800A1 (en) * 2004-12-14 2006-06-22 Pls-Design Gmbh Cloning of honey bee allergen
US20070003579A1 (en) * 2005-06-30 2007-01-04 Mannkind Corporation Allergen-specific immunotherapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
E H: "Separation and isolation of the hyaluronidase and phospholipase components of bee venom and investigation of bee venom-human serum interactions", TOXICON, ELMSFORD, NY, US, vol. 4, no. 3, 1 November 1966 (1966-11-01), pages 223, XP025540123, ISSN: 0041-0101, [retrieved on 19661101] *
KUSSEBI F ET AL: "A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 115, no. 2, 1 February 2005 (2005-02-01), pages 323 - 329, XP004775680, ISSN: 0091-6749 *
MARSH D G ET AL: "Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps.", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY DEC 1981, vol. 68, no. 6, December 1981 (1981-12-01), pages 449 - 459, XP002536342, ISSN: 0091-6749 *
MISTRELLO G ET AL: "MONOMERIC CHEMICALLY MODIFIED ALLERGENS: IMMUNOLOGIC AND PHYSICOCHEMICAL CHARACTERIZATION", ALLERGY, MUNSKGAARD, COPENHAGEN, vol. 1, no. 51, 1 January 1996 (1996-01-01), pages 8 - 15, XP008003438, ISSN: 0105-4538 *
MOLLAY C ET AL: "Enhancement of bee venom phospholipase A2 activity by melittin, direct lytic factor from cobra venom and polymyxin B", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 46, no. 1-2, 15 September 1974 (1974-09-15), pages 141 - 144, XP025945218, ISSN: 0014-5793, [retrieved on 19740915] *
MULLER ET AL: "Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 96, no. 3, 1 September 1995 (1995-09-01), pages 395 - 402, XP005111405, ISSN: 0091-6749 *
PASSALACQUA G ET AL: "Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 351, no. 9103, 28 February 1998 (1998-02-28), pages 629 - 632, XP004833160, ISSN: 0140-6736 *
SOLDATOVA ET AL: "Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 101, no. 5, 1 May 1998 (1998-05-01), pages 691 - 698, XP005686864, ISSN: 0091-6749 *
VALENTA R: "THE FUTURE OF ANTIGEN-SPECIFIC IMMUNOTHERAPY OF ALLERGY", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 2, no. 6, 1 June 2002 (2002-06-01), pages 446 - 453, XP008027639, ISSN: 1474-1733 *
YANG C C ET AL: "Carbamylation with cyanate of basic phospholipase A2 from the venom of Naja nigricollis (Spitting cobra)", TOXICON, ELMSFORD, NY, US, vol. 19, no. 6, 1 January 1981 (1981-01-01), pages 783 - 795, XP025540302, ISSN: 0041-0101, [retrieved on 19810101] *

Also Published As

Publication number Publication date
CA2708879A1 (en) 2009-07-02
RU2010130532A (en) 2012-01-27
ITMI20072421A1 (en) 2009-06-22
CA2708879C (en) 2018-07-31
ES2561594T3 (en) 2016-02-29
RU2481122C2 (en) 2013-05-10
EP2222337B1 (en) 2015-11-11
WO2009081440A2 (en) 2009-07-02
US8637037B2 (en) 2014-01-28
US20100297188A1 (en) 2010-11-25
EP2222337A2 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2009081440A3 (en) Allergens and allergoids from bee venom
WO2008021379A3 (en) Increased activity and efficiency of expansin-like proteins
WO2004053141A3 (en) Methods for rapid forensic analysis of mitochondrial dna and characterization of mitochondrial dna heteroplasmy
EP2805969A3 (en) Optimized FC variants
WO2008088747A3 (en) Method of monitoring hiv infection
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2011094259A3 (en) Cd127 binding proteins
WO2007006049A3 (en) Apparatuses, systems, and methods for isolating and separating biological materials
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007054160A3 (en) Method for the cryopreservation of human blood
WO2008092905A3 (en) Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
WO2011022357A3 (en) Fast acting snare-cleaving enzymes
WO2006082313A3 (en) T cd4+ epitopes of type i and ii latency antigens of the epstein-barr virus, which can be recognised by the majority of individuals in the caucasian population and applications thereof
WO2007021672A3 (en) Vaccination against dengue virus infection
WO2008085991A3 (en) Reaction chamber
WO2007082177A3 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2009049228A3 (en) Compositions and methods for assessing disorders
WO2012041867A3 (en) Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2009020596A3 (en) Embryonic cerebrospinal fluis (e-csf), proteins from e-csf, and related methods and compositions
WO2006031926A3 (en) Methods for the isolation and expansion of cord blood derived t regulatory cells
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2008095622A3 (en) SECRETED LUCIFERASE MLuc7 AND USE THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08865110

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008865110

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2708879

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010130532

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12809503

Country of ref document: US